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1. Introduction 
Meningiomas are brain tumors that originate from arachnoid cap cells. They account for 
about one third of all brain tumors (CBTRUS, 2011), and their incidence increases with age. 
There are many histological subtypes of meningioma and they differ in their level of 
malignant behavior. The most commonly used World Health Organization (WHO) scheme 
(see 2.1) classifies them in three grades, which have distinct prognostic properties. 
Malignant meningiomas (WHO grade III) are the most rare, but aggressive subtype of 
meningiomas. In comparison to other subtypes, they are understudied, likely due to their 
scarcity. The frequency of 1-3% among all intracranial meningiomas has been reported 
(Louis et al., 2007). 
In this chapter, we are bringing a review of the available literature on malignant 
meningiomas. Because of the rarity of these tumors, patients with malignant meningiomas 
represent a very small part of any study population. Most studies analyze information on 
meningiomas of all subtypes, and the data on malignant ones had to be extracted from the 
larger population. In the lack of randomized clinical trials, these sporadic experiences and 
case reports became the foundation for the current clinical practices in diagnosis and 
treatment of patients with this rare disease. Our review includes the information on 
meningiomas in general, with focus on malignant meningiomas whenever specific data is 
available. 
1.1 Frequency and Risk Factors 
1.1.1 Hormonal Factors 
Meningiomas in general are more common in women, with female predominance of 2-3 to 
1, but this tendency diminishes in atypical and anaplastic meningiomas, in children and in 
radiation-induced meningiomas (Marosi et al.; Park & McLaren, 2009). Hormonal factors 
have been considered to play a role in this predominance.  
A study on 125 women with meningiomas investigated the risk of meningiomas in relation 
to exogenous and endogenous sex hormones (Jhawar et al., 2003). The relative risk for 
premenopausal women was 2.48 and for postmenopausal women who received hormone 
therapy was 1.86. There was a nonsignificant increased risk of meningioma in parous as 
opposed to nulliparous women. The risk also trended up with increased BMI. No 
www.intechopen.com
 Meningiomas – Management and Surgery 
 
4 
association was found for past or current use of oral contraceptives. The risk for 
meningiomas was increased among women exposed to either endogenous or exogenous sex 
hormones. However, an unexpected relationship with increase in age at menarche was also 
noted and remained unexplained. 
Another study analyzed the relationship of exposure to female sex hormones and risk of 
brain tumors. It included 178 meningioma cases, 115 glioma cases and 323 controls 
(Wigertz et al., 2006). An increased relative risk of meningioma was found among 
postmenopausal women for ever use of hormone replacement therapy, with an odds 
ratio of 1.7. Women who had used long-acting hormonal contraceptives had an increased 
risk of meningioma. Hormone usage was not associated with glioma risk in this study. 
The findings suggest that the use of female sex steroids may increase the risk of 
meningioma. 
A large retrospective review of data on 355,318 women evaluated for any medical issue 
(Blitshteyn et al. 2008) was done to investigate the association between meningioma and 
hormone replacement therapy (HRT). Five percent of this population (18,037 women) was 
documented as current or past HRT users. A positive correlation between diagnosis of 
meningioma and HRT use was found, with odds ratio of 2.2. The frequency of meningioma 
in women with either current or past HRT use was 865 in 100,000, whereas the frequency in 
women without the history of HRT use was 366 in 100,000. Therefore, HRT use may be a 
risk factor for meningioma. 
1.1.2 Radiation 
Radiation-induced meningiomas have a higher rate of multiplicity and atypia, compared to 
sporadic meningiomas (Park & McLaren, 2009). Historically, low doses of irradiation were 
used in treatment of tinea capitis until 1950s, and the analysis of data on 10,834 treated 
children showed the sevenfold increase in the incidence of meningioma, with latency period 
shorter with higher doses of irradiation (Ron et al., 1988). A strong dose-response relation 
was found, with the relative risk approaching 20 after estimated doses of approximately 2.5 
Gy. Recurrences were more common in patients with radiation-induced meningiomas as 
compared to the sporadic.  
Another study on childhood cancer survivors (Neglia et al., 2006) showed that meningiomas 
developed in 0.5% of patients treated with cranial irradiation, with median time of diagnosis 
17 years after the diagnosis of original malignancy and the risk was directly related to the 
dose of cranial irradiation. 
An increased incidence of meningiomas was found in survivors of the atomic bomb 
explosions in Japan. The incidence was higher with higher radiation doses and in people 
who were younger at the time of exposure (Park & McLaren, 2009). 
1.1.3 Genetic Factors 
There is also increased frequency of meningiomas in certain genetic diseases, like 
neurofibromatosis (NF type I and II) and familial meningioma. The association with other 
malignancies is suggestive of a common genetic basis.   
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Tumorigenesis of meningiomas involves activation of oncogenes and the loss of tumor 
suppressor genes. NF2 tumor suppressor gene has been found to be mutated in a large 
portion of meningiomas (Maxwell et al., 1998). Almost all cases of familial meningioma 
occur in association with NF2. The authors of a case report on two family members with 
spinal meningiomas, without any NF2 stigmata, conclude that a second tumor 
suppressor gene locus, other than NF2 acts in formation of familial sporadic 
meningioma. The conclusion is based on the presence of protein product merlin in 
specimens from both patients. Merlin has been implicated in the tumorigenesis of 
meningiomas. 
1.1.4 Head Trauma 
There is some suggestion of increased risk of meningioma following head trauma. A large 
case-control study (Preston-Martin et al., 1998) was done to investigate this suggestion 
based on prior case reports. It involved 1178 patients with gliomas and 330 with 
meningiomas, matched to 2236 controls. Risks of ever having experienced a head injury was 
highest for male patients with meningiomas (odds ratio = 1.5), but was lower for “serious” 
injuries. Latency of 15 to 24 years significantly increased the risk of meningioma among 
males. Odds ratios were lower for males with gliomas for any injury and in females in 
general. This has shown that the brain tumor risk after head trauma was strongest for 
meningiomas in men. 
Another case-control study was conducted among women (Preston-Martin et al., 1980). One 
hundred-eighty-eight women with meningiomas were matched with their neighbors, and 
their experiences were compared. A history of head trauma was found to be associated with 
meningioma occurrence, with odds ratio of 2.0. 
2. Histopathology  
2.1 WHO Classification 
Meningiomas are classified according to the World Health Organization (WHO) schema, 
which is based upon morphologic criteria. The latest, 2007 version of WHO classification 
divides meningiomas into 3 groups (Louis et al., 2007; Park et al., 2010): 
 WHO grade I – Tumors that do not meet criteria for a higher grade lesion, based upon 
morphologic criteria. They are subdivided into: meningothelial, fibrous, transitional, 
psammomatous, angiomatous, microcystic, secretory, lymphoplasmacyte-rich and 
metaplastic. They are all considered to be of low risk for recurrence or aggressive 
growth and the treatment approach for all subtypes is the same. 
 WHO grade II – Tumors with increased mitotic activity (≥4 mitoses per high powered 
field) and three or more of the following features: increased cellularity, small cells with 
a high nuclear/cytoplasmic ratio, prominent nucleoli, uninterrupted patternless or 
sheet-like growth, or foci of spontaneous or geographic necrosis. Subtypes include: 
atypical, chordoid and clear cell meningiomas. Alternative grading approaches identify 
individually scored parameters to arrive at a sum (Jääskeläinen et al., 1986; Louis et al., 
2007), or simply combine hypercellularity with 5 or more mitoses per 10 high power 
fields. 
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 WHO grade III – Tumors with ≥20 mitoses per high-powered field and/or malignant 
characteristics resembling carcinoma, sarcoma or melanoma. Features that support the 
diagnosis of malignant meningioma include the loss of usual meningioma growth 
patterns, infiltration of underlying brain (Figure 1), abundant mitoses with atypical 
forms (Figure 2) and multifocal microscopic foci of necrosis (Figure 3). Subtypes 
include: papillary, rhabdoid and anaplastic (malignant) meningiomas. Although 
considered malignant, there are only isolated reports on any distant metastases. These 
tumors recur locally. 
The WHO grading system has been revised over the years to better delineate the categories 
of patients with similar outcomes. With 2000/2007 classification, the differences in 
progression-free survival between histologic groups became significant, as compared to 
1993. The major difference between 2000 and 2007 versions is that brain invasion became a 
criterion for classifying a meningioma as grade II or III, in a lesion that would otherwise be 
considered grade I. 
Changes in classification criteria are to be considered when literature is reviewed, as they 
brought on a substantial shift with increasing the numbers of patients with WHO grade II 
tumors. The refined WHO criteria appear to be more accurate prognostically. 
The likelihood of recurrence and/or aggressive behavior of meningioma increases with each 
higher grade. The proper classification of each tumor is very important in treatment 
planning. The tumors of lower grade can recur as a higher grade.  
One hundred-sixteen patients were diagnosed with “malignant meningioma” (Perry et al., 
1999) due to brain invasion, frank anaplasia (20 mitoses per 10 high-power fields or 
histology resembling carcinoma, sarcoma or melanoma) and/or extracranial metastasis. 
They were followed in a study, which concluded that histologic anaplasia, subtotal 
resection, 20 mitoses per 10 high-power fields and nuclear atypia were associated with poor 
survival. Survival time was highly variable, from 10 days to 24 years. Of 89 cases of 
meningioma that invaded the brain, 23% were otherwise benign, 61% were otherwise 
atypical and 17% were frankly anaplastic. Anaplastic meningiomas were usually fatal. Based 
on these findings it was suggested that the brain invasion constitutes an additional criterion 
for the diagnosis of atypical meningioma (WHO grade II), whereas frank anaplasia indicates 
high grade malignancy (WHO grade III) 
2.2 Pathological Features 
Papillary meningiomas are rare variant defined by the presence of perivascular 
pseudopapillary pattern in at least a part of the tumor. They tend to occur in children. Local 
invasion of the surrounding structures and invasion of the brain have been noted in 75% of 
these lesions, recurrence in 55% and metastasis in 20% (WHO, 2000). 
Rhabdoid meningioma is an uncommon tumor containing patches or extensive sheets of 
rhabdoid cells, which are  rounded tumor cells with eccentric nuclei, often with a prominent 
nucleolus, and prominent inclusion-like eosinophilic cytoplasm comprised of whorled 
intermediate filaments. Most rhabdoid meningiomas have high proliferative indices and 
additional histological features of malignancy (WHO, 2000). 
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Anaplastic (malignant) meningiomas are tumors exhibiting histological features of frank 
malignancy far in excess of the abnormalities present in atypical meningiomas. This 
includes either obviously malignant cytology or a high mitotic index (≥20 mitoses per 10 
high-power fields) (WHO, 2000). They are found to have a high proliferation rate as well 
(Figure 4). 
 
 
 
Fig. 1. Brain (B) Invasion. H&E, X10 (original magnification) 
 
   
 
Fig. 2. Mitoses (white arrows). H&E, X60 (original magnification) 
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Fig. 3. Necrosis (N). H&E, X4 (original magnification) 
 
Fig. 4. High proliferation index. Ki67 (MIB-1) cell proliferation marker. 
Immunohistochemistry. DAKO Envision Flex+ with or without heat induced epitope 
retrieval techniques. X20 (original magnification) 
3. Imaging Characteristics 
Diagnostic process on patients with intracranial masses typically starts with brain imaging, 
after the initial clinical assessment. Oftentimes, intracranial masses can be incidental 
findings on the imaging done for unrelated reasons, such as work-up for head trauma. The 
most common clinical scenario is a finding of suspicious lesion on a plain computed 
tomography (CT), which is then followed by gadolinium enhanced magnetic resonance 
imaging (MRI).   
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Fig. 5. Contrast enhanced CT image of clival meningioma in a 69-year-old man. Dural tail is 
visible. 
 
Fig. 6. Axial T1 MRI with gadolinium of the left sided convexity meningiomas in a 62-year 
old woman. Anterior lesion has visible dural tail. 
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This applies to meningiomas as well. Although a definitive diagnosis cannot be made solely 
based on imaging, there are some features that can be suggestive of meningiomas. 
The most common locations for meningiomas (in descending order) are in parasagittal dura, 
convexities, sphenoid wing, cerebellopontine angle cistern, olfactory groove and planum 
sphenoidale. Ninety percent occur supratentorially. One percent of meningiomas occur 
outside the CNS, presumably from embryologic arachnoid rests. Because meningiomas arise 
from arachnoid cap cells, they can occur anywhere that arachnoid exists (Grossman & 
Yousem, 2003) 
The grade of tumor cannot be determined based on imaging, but the benign lesions tend to 
appear as well demarcated, ovoid extradural masses. With increase in tumor grade, the 
lesions tend to lose their sharp contours, often demonstrating invasion of surrounding brain 
tissue, bone and/or venous sinuses. Necrotic centers and calcified portions can be seen as 
well. 
A retrospective study on 75 patients who underwent intracranial meningioma resection was 
done to determine correlation between aggressive imaging features and advanced 
histopathological grade in meningiomas (Hsu et al., 2010). Six aggressive imaging features 
were evaluated: intratumoral cystic change, hyperostosis of the adjacent skull, bony 
destruction, extracranial tumor extension through the skull base foramina, arterial 
encasement and peritumoral brain edema. Fifty-nine tumors were classified as benign, 
according to WHO classification, and 16 as atypical/malignant. Only intratumoral cystic 
change and extracranial tumor extension through the skull base foramina were more 
prevalent in atypical/malignant meningiomas. 
 “Dural tail” is highly characteristic of meningioma and it has been seen in up to 72% of the 
cases (Grossman & Yousem, 2003). The dura is trailing off away from the lesion in crescentic 
fashion (Figures 5 & 6). 
The degree of parenchymal edema is variable in meningiomas, and it is not necessarily 
proportionate to their size. It seems to correlate with location, because meningiomas 
adjacent to cerebral cortex tend to incite greater edema than those along the basal cisterns or 
planum. It may be caused by compressive ischemia, venous stasis, aggressive growth or 
parasitization of pial vessels (Grossman & Yousem, 2003). 
Bony changes associated with meningiomas may be hyperostotic or osteolytic and occur in 
20% to 46% of cases (44). They can be suggestive of malignant behavior, but the hyperostosis 
along the inner table only can be just the reactive changes rather than neoplastic invasion. 
Secondary bone involvement occurs in up to 50% of skull base meningiomas. It is 
uncommon in convexity tumors (Park & McLaren, 2009). 
3.1 Magnetic Resonance Imaging (MRI) 
MRI is preferred in imaging meningiomas, as it is superior in demonstrating dural origin, as 
well as vascularity, edema, sinus and bone invasion. Meningiomas are typically isointense 
or hypointense to gray matter on T1 and isointense or hyperintense on T2 weighted images 
(Figure 7). They enhance with gadolinium, but they might have areas of necrosis and 
calcification, which do not enhance. 
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Fig. 7. Axial MRI of a right parasagittal anaplastic meningioma in a 72-year-old woman. 
Image on the left is FLAIR T1, in the middle is T2 and on the right is T2 FLAIR with 
gadolinium. 
3.2 Computed Tomography (CT)  
CT scans typically show well-defined, smooth-contoured extra-axial mass, which displaces 
the normal brain tissue. Sometimes meningiomas can be multilobulated or calcified. They 
can be isointense with the normal brain tissue, but they enhance uniformly with the 
intravenous contrast administration, making the diagnosis easier. This is more typical of 
benign meningiomas. 
Characteristics suggestive of aggressive behavior (Figure 8) of the tumor are: indistinct margins, 
marked edema, mushroom-like projections from tumor, deep brain parenchymal infiltration 
and heterogenous enhancement (Shapir et al., 1985 as cited in Park & McLaren, 2009). 
 
Fig. 8. CT image of a right parasagittal anaplastic meningioma in a 69-year-old woman 
(same patient as in Figure 7, three years earlier) 
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3.3 Positron Emission Tomography (PET)  
PET is not routinely used in diagnostics of meningiomas, but it has its place in diagnostics of 
malignant meningiomas, considering that it can help predict aggressiveness of a 
meningioma and the potential for recurrence (Di Chiro et al., 1987; Park & McLaren, 2009). 
3.4 Angiography  
Angiography was used more often prior to development of MRI and CT techniques. 
Findings of arterial supply from meningeal vessels and the delayed vascular blush were 
helpful in diagnosis of meningiomas. They have both dural and pial supply. Angiography is 
now mainly used as part of the pre-operative embolization procedures. 
4. Treatment 
The National Comprehensive Cancer Network® (NCCN®) guidelines summarize the 
contemporary approach to meningioma management (NCCN®, 2011): 
 
 
Reproduced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN 
Guidelines™) for Central Nervous System Cancers V.2.2011. © 2011 National Comprehensive Cancer 
Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be 
reproduced in any form for any purpose without the express written permission of the NCCN. To view 
the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. NATIONAL 
COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES™, and all other NCCN 
Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 
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This subchapter contains the review of available literature on various modalities of 
treatment supplemented with experiences from our own institution. The existing data on 
therapy most commonly comes from retrospective studies on patients with all types of 
meningiomas, with only small subgroups having malignant forms. The lack of hard 
evidence on efficacy of different treatment approaches makes it difficult to standardize the 
treatment algorithm for malignant meningioma. However, the general consensus is that 
surgical resection, as radical as possible, should be performed. If indicated, a pre-operative 
embolization should be done a day before resection. Radiation therapy following surgery is 
found to be beneficial, and therefore it became a standard of care for these patients. Various 
modalities of systemic therapy have been tried, mostly on patients who have exhausted all 
primary options, but unfortunately, their efficacy has not been very promising so far. 
4.1 Embolization 
As malignant meningiomas are highly vascular tumors, preoperative embolization can 
make them more resectable. It is most applied to skull base meningiomas, a day prior to 
surgery (Carli et al., 2010; Matsuda et al., 2011; Oka et al., 1998; Rosen et al., 2002). 
Again, the information on malignant meningiomas alone is very scarce. Available sources 
provide information on meningiomas in general.  
A retrospective analysis on 167 cranial base meningiomas (Rosen et al., 2002), which were 
embolized showed that a good to excellent embolization was achieved in 91% of patients, 
without permanent neurological sequelae. Cranial base meningiomas were defined as 
tumors originating from olfactory groove, tuberculum sellae, medial sphenoid wing, petro-
clival region or foramen magnum. In 20 patients, embolization was not attempted due to the 
risk of new neurologic deficits or lack of an appropriate vessel for embolization. Fifteen 
patients (9%) experienced permanent neurologic deficits or medical morbidity as a result of 
embolization. The conclusion of this study points out that the benefits of embolization as an 
adjunct to cranial base surgery have to be weighted against the morbidity that comes with 
this procedure. 
Another study involving 20 patients with skull-base meningiomas (Oka et al., 1998) revealed 
significantly smaller blood loss during surgical resection in patients who underwent pre-
operative embolization. This only applied to tumors smaller than 6 cm. There was no 
difference in blood loss in tumors larger than 6 cm, perhaps because larger meningiomas 
tend to have tiny blood vessels that are unsuitable for pre-operative embolization. There 
was no difference in the length of surgery between the embolized and non-embolized 
group. However, the embolized group tended to show better clinical outcome.  
The risks of widely used particle embolization (Carli et al., 2010) were analyzed on 198 
patients (201 meningiomas). Indications for embolization were: pre-operative in 165 
meningiomas, adjunctive to radiosurgery in 8 and sole therapy in 28. Complications were 
defined as any neurologic deficits or death that occurred during or after embolization. They 
occurred in 11 patients (5.6%); 10 were hemorrhagic and 1 ischemic. Complications of 
embolization resulted in death of 2 and dependency in 5 patients. The use of small particles 
(45-150 µm) was the only risk factor for complications. With the complication rate of 5.6% 
and the increased risks with small particles, the use of small polyvinyl alcohol particles is 
not recommended. 
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Another study (Matsuda et al., 2011) assessed the atypical and ischemic features of 
embolized meningiomas, comparing 29 patients that underwent pre-operative embolization 
with 29 who did not. Large polyvinyl alcohol particles (150-250 µm) were used for 
embolization via middle meningeal or occipital artery, until the stagnation of the contrast 
agent in the feeding artery was accomplished. The embolization material was invisible in 
tumors and the large particles were believed to remain in the feeding vessels. Small cells, 
clear cells, rhabdoid-like cells and pseudopapillary pattern were thought to be associated 
with embolization using the large particles, instead of development of necrosis. There were 
no complications of the embolization procedure. Embolization was done 3 to 355 hours 
before the surgical extirpation. The two groups of patients had no significant differences in 
gender, age, tumor location and reoccurrence or regrowth of tumor. However, the 
differences in histopathological features between the two groups were evident. They 
included higher mitotic activity, brain invasion, increased cellularity, prominent nucleoli, 
small cells with high nuclear/cytoplasmic ratio, sheet-like growth and geographic necrosis. 
Even more evident differences were noted in occurrence of cytoplasmic vacuoles, 
intercellular discohesion and perivascular cuffs. In accordance to WHO 2007 classification, 
11 patients (38%) in embolized group were classified as grade II atypical meningioma, 
versus 7 patients (24%) in non-embolized group. There were no patients with anaplastic 
(grade III) meningiomas. It appears that the increased frequency of atypical features in pre-
operatively embolized meningiomas could lead to prognostic inaccuracies and overly 
aggressive therapy. However, the possibility of patient selection bias rather than 
embolization artifacts leading to higher number of atypical meningiomas in embolized 
group cannot be excluded, especially considering a rather small patient sample. Proliferative 
activity in embolized meningiomas does not always reflect genuine tumor proliferation and 
should not be used to assess malignancy. Ischemic histologic features (including small cells 
with high N/C ratios, cytoplasmic vacuoles, intercellular discohesion and perivascular 
cuffs) were identified in embolized meningiomas. Therefore, histological findings and 
determination of grading should be evaluated cautiously in the cases of embolized 
meningiomas. 
4.2 Surgical Options 
Complete surgical resection, including its dural attachement is a preferred therapeutic 
approach for all meningiomas, including malignant. As delineated in NCCN Guidelines 
(NCCN, 2011; see above), surgery is the first line of treatment for all symptomatic and for 
large asymptomatic meningiomas. As meningiomas are highly vascular, pre-operative 
embolization is often used (see 4.1).  With advances of modern imaging techniques, 
microsurgery and image-guided intraoperative approaches, this can be achieved in most 
tumors at accessible locations, minimizing the damage to normal brain tissue. However, 
malignant meningiomas often cannot be completely resected. Subtotal resection is then 
combined with radiation therapy (see 4.3). The extent of surgery is balanced with 
minimizing neurological deficits possibly caused by resection. Complete resection is usually 
attempted for tumors of the convexity, olfactory groove, anterior third of the sagittal sinus 
and some tentorial and posterior fossa tumors. Posterior sagittal region or clivus are less 
accessible, thus commonly allowing for partial resection, which is then followed by 
radiation therapy. Tumors involving medial sphenoid wing or cavernous sinus are deemed 
inaccessible, and surgery is generally not attempted. 
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4.2.1 Extent of Resection and Tendency for Recurrence 
The extent of surgical resection is described with Simpson grading system (Simpson, 1957), 
still widely accepted since its publication: 
 Grade I – Macroscopically complete removal of the tumor, with excision of its dural 
attachment and of any abnormal bone. Includes resection of venous sinus, if involved. 
 Grade II – Macroscopically complete removal of the tumor and of its visible extensions, 
with coagulation of its dural attachment. 
 Grade III – Macroscopically complete removal of the intradural tumor, without 
resection or coagulation of its dural attachment or its extradural extensions (e.g. an 
invaded sinus or hyperostotic bone). 
 Grade IV – Partial removal, leaving intradural tumor in situ. 
 Grade V – Simple decompression, with or without biopsy. 
The author (Simpson, 1957) analyzed the post-operative results of two series of patients, one 
of 235 cases (operated on in Oxford, from 1938 to 1954) and one of 97 cases (London, from 
1928 to 1938). A system of grading according to the scope of resection was presented and 
applied to those cases, 265 in all, surviving more than six months. Following 90 operations 
of grade I, there were 8 recurrences (9%). Following 114 grade II resections, there were 18 
recurrences (19%, with cases treated within the last 5 years of study period being excluded). 
These recurrences became apparent after an average period of five years. Long-delayed 
recurrences, though clearly possible, appeared unusual. After incomplete resections, grades 
III-V, the incidence of symptomatic recurrence was naturally much greater, but a number of 
patients treated by limited excisions were given long periods of relief. In this study, the 
author emphasized that in the clinical sense, meningiomas may be benign, locally invasive 
or frankly malignant. The frequency of local infiltration of venous sinuses was found in 15% 
of cases, infiltration of bone in 20% and of brain in 3.7%. Haematogenous metastasis was 
found in two patients. 
Though this study was conducted more than a half century ago, its general observations are 
still considered relevant and the new data is only confirming them. Simpson grading system 
for the extent of surgery is commonly used today in its original form. However, some 
authors propose adding grade 0 to it (Borovich et al., 1986), entailing a wide resection of the 
dura around the attachment zone of the meningioma. 
More contemporary data reflect the advances of modern surgical techniques and overall 
medical treatment. Publications regarding malignant meningiomas specifically are still 
scarce and the few existing studies are retrospective. They all do point to the increased 
benefit of surgery followed by radiotherapy. With the lack of prospective studies on the use 
of post-operative radiotherapy for malignant meningiomas, it has nevertheless come to 
represent the standard of care at most institutions (Hanft et al., 2010). 
One retrospective study of 38 patients with 48 malignant meningioma resections (28 total 
and 20 subtotal) was done to determine the time to recurrence, among other parameters 
(Dziuk et al., 1998). Twenty-five lesions were treated at initial presentation and 23 were 
treated as recurrent disease (13 had transformed from previously benign meningiomas). 
Nineteen patients received post-operative radiation therapy. Histological subtypes included 
32 anaplastic meningiomas, 11 hemangiopericytomas, 2 meningiosarcomas and 3 papillary 
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meningiomas. One patient presented with multicentric disease, and 4 had multicentric 
disease at recurrence. Tumors were located on frontal/parietal convexity in 33%, 
falx/parasagittal sinus in 26%, temporal convexity in 10%, tentorium and posterior fossa in 
5% each, and in occipital convexity, sphenoid wing, olfactory groove, tuberculum sellae and 
foramen magnum in 3% of lesions per each location. Eight percent of patients had lesions at 
multiple sites. Follow-up ranged from 3 to 144 months, with 5 patients excluded from 
analysis. Disease free survival (DFS) at 24 months for all patients was 74%, and at 5 years it 
was 25%. DFS at 5 years was 39% following total resection versus 0% after subtotal 
resection. For all totally resected lesions, the 5-year DFS was improved from 28% for surgery 
alone to 57% with adjuvant radiotherapy. As there were no distant failures, local control 
was equated to actuarial DFS. Twenty out of 26 surgery alone meningiomas recurred, as did 
7 of 17 receiving adjuvant radiotherapy. Combined results for surgery with and without 
adjuvant radiation revealed the following: When analyzed by extent of resection, there was 
a trend to increased DFS at 24 months, 80% for total resection versus 66% for subtotal 
resection. It was significant at 5 years, with 39% versus 0%. Initially treated lesions 
displayed a higher rate of local control versus recurrent lesions, with a 5-year DFS of 33% 
versus 19% respectively. Totally excised lesions treated with surgery alone had 5-year DSF 
of 28%, compared to 0% for the subtotally excised lesions. The 5-year DFS of surgery alone 
patients was essentially the same for initial versus recurrent resections. However, the 
median time to local failure was significantly longer for initial versus recurrent disease, 43.5 
months versus 18 months, respectively.   
Recurring lesions have an increased tendency toward multicentricity, and multicentric 
lesions have an increased tendency for recurrence. Once disease has recurred, there is an 
increased probability for a subsequent local failure, and the disease/progression-free 
interval is shortened (Salazar, 1988 as cited in Dziuk et al., 1998).  
Probability for local control was once again shown to be dependent upon the extent of 
resection. The meningioma location impacts the potential for total resection: the most 
accessible convexity lesions are completely resected in 96% of cases, parasagittal/falx 
tumors 80%, olfactory groove 70%, sphenoid ridge 50%, tuberculum sellae 48% and 
posterior fossa 43% (Salazar, 1988 as cited in Dziuk et al., 1998). However, total resectability 
by location does not translate into decreased recurrence by location: the parassagittal region 
is commonly reported to have the highest recurrence rate. The difference is presumed due to 
the resection of as little dura as possible in the meningiomas of the middle and posterior 
sagittal sinus to avoid occlusion. 
The tendency of meningiomas to recur even after they appeared to the naked eye as 
completely surgically removed (Simpson grade I) is attributed in some cases to malignancy 
and more commonly to an erroneous belief that the excision was total (Borovich & Doron, 
1986). In a study on 14 patients with globular meningiomas (Borovich & Doron, 1986), 
authors examined the dura mater around the meningiomas for evidence of regional 
multifocality. Meningotheliomatous cell aggregates were demonstrated in 100% of dural 
strips, which were removed from the line of attachment of each globular meningioma. The 
cell aggregates were in the form of dural clusters or nodes protruding from the inner aspect 
of the dura. They appeared benign. Control strips of convexity dura mater taken from 10 
neurosurgical patients without meningioma failed to show these meningotheliomatous 
conglomerates. These findings indicate that solitary globular meningiomas represent only 
www.intechopen.com
 Management of Malignant Meningiomas 
 
17 
the most visible growth in the midst of a neoplastic field change spreading over a wide area 
of dura mater. 
Regional multiplicity in meningiomas would thus seem to be rule (Borovich et al., 1986). The 
authors of this study proposed dividing recurrences after grade I resections into true local 
and false regional. A local recurrence would be defined as a regrowth within the limits of 
the previous dural flap. Regional recurrence would be the new growth outside the previous 
craniotomy site, which should not be considered as a recurrence but as a new primary site. 
With the idea that a wider resection of the dura around the attachment zone of the 
meningioma would reduce the incidence of recurrence, the authors proposed adding 
Simpson grade 0 to the existing classification, defining more radical total resection. 
In a large cohort study (Sughrue et al., 2010) of 63 patients with WHO grade III 
meningiomas, all the patients underwent post-operative radiation therapy after the primary 
surgery and they were followed for median time of 5 years. Fifty-eight percent of those 
patients who underwent a second surgery for recurrent meningioma received either 125I 
brachytherapy implants or gamma-knife radiosurgery. Nearly 50% of patients had 
radiographic recurrence. The 2-, 5- and 10-year overall survival rates following initial 
surgery were 82, 61 and 40%, respectivelly. There was a significant survival benefit with 
repeat surgery for recurrent meningiomas (median survival of 53 months versus 25 months). 
Interestingly, patients treated with near-total resection experienced improved overall 
survival when compared with patients treated with gross-total resection at initial and repeat 
operations. Twelve (19%) of 63 patients experienced significant neurological morbidity 
referable to the resection of their tumors. 
4.2.2 Surgical Morbidity and Mortality  
The reported incidence of neurologic deficits as a direct complication of surgery ranges from 
2 to 30%, depending on the location of the tumor and the extent of resection. Cortical brain 
injury may occur if the arachnoid and pia are adherent to the tumor and the pial vasculature 
is disrupted. Surgeries for skull base meningiomas pose risk for cranial nerve deficits. 
The reports on overall surgical mortality vary with patient selection, as well as with changes 
in surgical care. 
The cumulative observed survival rate of 935 patients who underwent surgery for 
intracranial meningioma (operated on between 1953 and 1980) was 91% at 3 months, 89% at 
1 year and 63% at 15 years (Kallio et al., 1992). Significant risk factors for operative mortality 
(7%) for the 652 patients (operated on from 1966 to 1980) were poor preoperative clinical 
condition, absence of epilepsy, old age, incomplete tumor removal, pulmonary embolism 
and intracranial hematoma requiring evacuation. In 828 patients who survived the first 
post-operative year, the excess risk of death for up to 15 years was related to incomplete 
tumor removal, poor pre- and post-operative clinical condition, anaplasia of the tumor and 
hyperostosis. Patients with partial resections had a 4.2-fold relative excess risk of death as 
compared to patients with complete resections of tumors. Also, patients with malignant 
tumors had a 4.6-fold risk as compared with those who had benign tumors. 
The higher mortality in older age population can be found in many older reports. However, 
the advances in surgical techniques as well as a careful selection of surgical candidates 
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among the elderly have the potential of changing this picture. A retrospective study on 17 
patients who underwent surgery for intracranial meningioma in their 9th decade of life 
(Mastronardi et al., 1995) showed that severe systemic disease and functional limitations 
had a major post-operative morbidity and mortality. The risk of post-operative morbidity 
was higher when the maximum diameter of the tumor was >5 cm. 
4.2.3 Peri-operative Management  
Seizures can be the sole symptom at the initial presentation of patients with meningioma, as 
well as the part of the more complex presentation. They can also occur post-operatively. 
Prophylaxis with anticonvulsant medications prior to surgery in patients who never had 
seizures is not indicated. Post-operative prophylaxis on patients undergoing resections of 
supratentorial tumors is indicated, with gradual tapering and discontinuing the medication 
in patients who had no seizures. 
Cerebral edema is managed with administration of corticosteroids, which are post-
surgically tapered if clinically feasible. 
Deep venous thrombosis (DVT) appears to be especially problematic in patients with 
meningiomas, both because of the generally increased risks of DVT in patients undergoing any 
brain surgery and because meningiomas can produce hypercoagulable state. In 46 patients who 
underwent brain tumor resections, the incidence of DVT was 72% for meningioma patients, 
60% for glioblastoma patients and 20% for brain metastasis patients (Sawaya et al., 1992). There 
was no correlation between the occurrence of DVT and the “usual suspects” among the risk 
factors for DVT. This finding, along with the marked variation in the incidence of DVT between 
the different brain tumor groups, strongly suggests that bilological factors play more important 
role than clinical factors in developing post-operative thrombosis. Pre-operative hemostatic 
profile was further investigated on 42 brain tumor patients (Sawaya & Glas-Greenwalt, 1992) 
and the occurrence of DVT was found to be higher with increased prothrombin time, 
plasminogen and total fibrinolytic activity and with decreased fibrinogen level. This overall 
trend in the group of patients with DVT after brain tumor resection lead to the conclusion that 
this hemostatic disorder is most closely related to a subclinical form of chronic disseminated 
intravascular coagulation syndrome. Pneumatic compression boots and prophylactic 
anticoagulation post-operatively for all patients with brain tumors should be considered. 
4.3 Radiation Therapy 
Radiation therapy is used in addition to subtotal surgical resection of meningiomas, as a sole 
therapy for unresectable tumors and oftentimes for completely resected tumors with high risk 
of recurrence per their histopathological features. Like with other therapeutic modalities used 
for the treatment of meningioma, there are no randomized trials providing evidence of its 
efficacy and safety. The available observational studies uniformly show the improvement in 
progression-free survival of patients who received radiation as compared to those who did not.  
4.3.1 Effectiveness of Radiation Therapy 
There is no general agreement on the use of radiation for partially removed tumors 
immediately after the initial surgery or upon the development of recurrence. Just like in 
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surgical therapy, the techniques in radiation therapy have significantly improved overtime. 
The improvement of imaging techniques have contributed to better results as well.  
This was clearly shown in a retrospective analysis of 140 patients who received radiation 
therapy as an adjuvant to subtotal resection of intracranial meningiomas, from 1967 to 1990 
(Goldsmith et al., 1994). Of 140 meningiomas, 117 were benign and 23 were malignant. The 
overall survival rate at 5 years was 85% for the benign and 58% for the malignant tumor 
groups; the 5-year progression-free survival (PFS) rates were 89% and 48%, respectively. 
The 10-year overall and PFS rates for patients with benign meningiomas was 77%. 
Improvement in this rate was not related to tumor size, but to a younger age and treatment 
after 1980 (when CT and MRI became available for planning therapy). Prior to 1980, the 
radiation therapy volumes were based exclusively upon the surgeon’s assessment of the site 
and volume of residual disease. Availability of CT and/or MRI allowed for incorporating 
more precise information about the residual tumor into the radiation planning. The 5-year 
PFS rate for patients with benign meningiomas treated after 1980 was 98% versus 77% for 
patients treated before 1980. Survival also improved with increasing the minimum radiation 
dose. None of these factors affected the survival rates of patients with malignant 
meningiomas.  
The objective of the study on 101 patients with skull base meningiomas was to analyze long-
term local control and complications after radiotherapy (Mendenhall et al., 2003). Sixty-six 
patients were treated with radiotherapy alone and 35 were treated with radiotherapy after 
subtotal surgical resection. Sixty-one patients had previously untreated tumors and 40 had 
tumors that recurred after prior surgery. The long-term local control rates were 95% at 5 
years, 92% at 10 years and 92% at 15 years. The probability of long-term progression-free 
survival after radiotherapy exceeded 90% and was comparable to the results of complete 
resection and radiosurgery.  
The effectiveness of radiotherapy was assessed in a retrospective study of 119 patients with 
atypical (69%) or malignant (31%) meningiomas treated with external beam radiotherapy 
(EBRT) after initial complete resection in 94 cases and for recurrence in 25 patients (Pasquier 
et al., 2008). The overall survival rates at 5 and 10 years were 65% and 51%, respectively. 
They were influenced by age over 60 years, low Karnofski performance status and high 
mitotic rate. The 5- and 10-year disease-free survival rates were 58% and 48%, respectively 
and were significantly affected by Karnofski performance status and high mitotic rate. 
In a study on 936 primary intracranial meningiomas (Jääskeläinen et al., 1986), 94.3% were 
histologically benign (WHO grade I), 4.7% were atypical (grade II) and 1% were anaplastic 
(grade III). Only 26% of atypical or anaplastic meningiomas appeared completely innocent 
on a CT scan. Five years after complete removal, the recurrence rate was 3% for benign 
meningiomas, 38% for atypical and 78% for anaplastic ones. In spite of post-operative 
radiotherapy, four out of five anaplastic meningiomas recurred. This data supports the 
widely accepted practice of using radiation as adjuvant therapy for meningiomas of WHO 
grade II and III even after gross total resection, due to the increased rate of recurrence of 
these tumors, even though the effectiveness for malignant meningiomas specifically appears 
modest.  
Previously cited analysis of 38 patients with malignant meningiomas, 19 of which received 
post-operative radiotherapy (Dziuk et al., 1998, see 4.2.1), showed that the adjuvant 
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radiation following initial resection increased the 5-year disease-free survival (DFS) rates 
from 15% to 80%. When administered for recurrent lesions, adjuvant radiotherapy 
improved the 2-year DFS from 50% to 89%, but had no impact on 5-year DFS. Multivariate 
analysis indicated that the extent of resection, adjuvant radiotherapy and recurrence status 
were independent prognostic factors.  
4.3.2 Dosage and Toxicity 
The authors of the above-mentioned study (Dziuk et al., 1998) also pointed out the 
importance of treatment volume, recommending 3-4 cm margins around the pre-operative 
tumor volume. The dose response was established, with recommendation of 60 Gy at 
conventional fractionation. The adjuvant radiotherapy for the 9 subtotally resected lesions in 
this study did not provide long-term benefit, but 7 of them received 54 Gy or less. 
The importance of radiation dose is illustrated by a retrospective series of 140 patients with 
benign or malignant meningiomas (Goldsmith et al., 1994), as described above (see 4.3.1). Of 
117 patients with benign meningiomas, those treated with doses >52 Gy had better 10-year 
survival (93% versus 65% with 52 Gy). Similarly, among the patients with malignant 
meningiomas, the 5-year progression-free survival was better with doses >54 Gy (63% 
versus 17% with doses  53 Gy). 
Available literature uniformly recognizes the increased efficacy of radiotherapy that comes 
with the increased doses, which of course, has to be balanced with the risks of injury for 
surrounding tissue. There is, however, little variation on recommended dose. Per (Park et 
al., 2010), when radiation therapy is applied post-operatively for residual disease, a dose of 
54 Gy is used in daily fractions of 1.8 to 2 Gy for benign meningiomas. Atypical and 
anaplastic meningiomas are treated with higher doses, typically 59.4 Gy.  
The recommended dose of adjuvant radiotherapy for best long-term control per (Dziuk et al., 
1998) is 60 Gy (especially for subtotally resected disease) and it should be administered 
simultaneously with an initial complete resection. A 4 cm margin for the initial 50 Gy is advised. 
4.3.3 Types of Radiotherapy  
The goal of any type of radiation therapy is to deliver maximum dose of radiation to the 
lesion, while sparing the surrounding viable tissue. The commonly used techniques are 
stereotactic radiosurgery (SRS), stereotactic radiotherapy (SRT) and intensity-modulated 
radiation therapy (IMRT) (50). There is some preliminary data on proton beam therapy, 
which might be useful. Boron neutron capture therapy (BNCT) was tried on two patients, 
one of whom had anaplastic meningioma (Aiyama et al., 2011). The conclusion was that 
BNCT could be a safe palliative therapy for malignant brain tumors. 
SRS utilizes multiple convergent beams to deliver a high single dose of radiation to a 
radiographically discrete treatment volume, thereby minimizing injury to adjacent structures 
(Park et al., 2010b). It is used for tumors in close proximity to critical structures (ex. optic 
nerve). Radiation alone can be also used for tumors in inaccessible locations like cavernous 
sinus or medial sphenoid wing. The most well-known machine used is Gamma-Knife®, 
utilizing cobalt-60. It is best used on lesions of ≤ 3.5 cm in size. The typical dose used to treat 
meningiomas is 12-14 Gy to the 50% Isodose line. This is done at a single sitting. 
www.intechopen.com
 Management of Malignant Meningiomas 
 
21 
SRT is similar to SRS, using focused radiation, only fractionated over a series of sessions 
(Park et al., 2010b). Fractionation improves normal tissue tolerance of radiation, so SRT may 
be a reasonable alternative for patients with surgically inaccessible lesions. These machines 
are linear accelerator based and they are more suitable for use on tumors > 3.5 cm in size. 
The most common machines are CyberKnife® and Novalis Tx®. 
IMRT relies upon software and modification of standard linear accelerator output to vary 
the radiation intensity across each treatment field (Park et al., 2010b). Similarly to SRS and 
SRT, it is useful for targets juxtaposed to radiation-sensitive structures. It is also particularly 
valuable for treatment of lesions with complex shape, such as those involving the skull base. 
4.4 Systemic Treatment 
Despite advances in surgery, radiation therapy and radio-surgery, there remains a small but 
important subset of patients with meningiomas who develop recurrent disease refractory to 
conventional therapies. To date, chemotherapies have shown minimal activity and 
hormonal therapies have proven to be largely ineffective. Progress in identifying alternative 
forms of therapy for these patients has been limited by poor understanding of the molecular 
pathogenesis of meningiomas and the critical molecular changes driving tumor growth, and 
by the lack of meningioma cell lines and tumor models for preclinical studies (Wen et al., 
2010). 
Most data is collected from observational studies, and unfortunately, none of the agents 
have proven efficacy in progression-free overall survival. 
4.4.1 Hormonal Therapy  
Epidemiologic data on meningiomas is suggestive of a link between hormonal factors and 
development or progression of these tumors. The data has been controversial, with 
meningiomas being more frequent among women who had multiple pregnancies and 
among patients with history of breast cancer. However, early menarche and late menopause 
have not increased the risk of developing meningioma (Grunberg et al., 1991; Wen et al., 
2010). Progesterone and androgen receptors are expressed on approximately two thirds of 
meningiomas and estrogen receptors are expressed on approximately 10% (Wen et al., 2009). 
Progesterone receptors are predominantly expressed in benign meningiomas with low 
proliferation indices and they are infrequently expressed in atypical and malignant 
meningiomas (Wolfsberger et al, 2004). Again, data for malignant meningiomas specifically 
is limited, likely due to their scarcity. Inhibition of sex hormone receptors has been tried in 
attempt to alter the course of recurrent meningioma, but without significant success. 
4.4.1.1 Progesterone Receptor Inhibition  
Progesterone receptor inhibition initially appeared promising, as several small studies 
showed some efficacy of anti-progestational drug mifepristone.  
A group of 10 patients with 12 recurrent or primary inoperable meningiomas with recent 
evidence of tumor growth received 200 mg of mifepristone daily for 12 months (Lamberts et 
al., 1992). Progression of growth of 5 tumors in 4 patients, stable disease in 3 patients and 
regression of 4 tumors in 3 patients was shown on CT scan analysis. Five patients had 
www.intechopen.com
 Meningiomas – Management and Surgery 
 
22
subjective improvement in headache and general well-being. Mifepristone treatment 
resulted in control of tumor growth in 6 out of 10 patients. Three of them were noted to have 
tumor shrinkage. 
Another study followed 14 patients with unresectable meningiomas treated with 200 mg of 
mifepristone daily for 2 to over 31 months (Grunberg et al., 1991). Five patients have shown 
signs of objective response, 3 have experienced subjective improvement. 
These results prompted more comprehensive investigations. A phase III double-blind placebo-
controlled randomized study analyzed data on 160 patients with unresectable non-malignant 
meningiomas, which have appeared or progressed within two years prior to enrollment 
(Grunberg et al., 2001). Patients were randomized to mifepristone and placebo group, 80 
patients per arm. There was no significant difference in response: two mifepristone-treated 
patients and one placebo-treated patient had partial or unconfirmed responses.  
A study following 28 patients with unresectable meningiomas treated with mifepristone for 
median duration of 35 months (Grunberg et al., 2006) has shown minor responses in 8 
patients, 7 of whom were male or premenopausal female. The most common side effects 
were fatigue, hot flashes and gynecomastia/breast tenderness. Endometrial hyperplasia or 
polyps were noted in 3 patients and one patient developed peritoneal adenocarcinoma after 
9 years of therapy.  
Overall, the long-term administration of mifepristone appears to be clinically well tolerated, 
with modest effect on tumor control, better in subgroup of male and premenopausal female 
patients. Mifepristone’s lack of efficacy may be explained in part by the loss of progesterone 
receptor expression in meningiomas with increased proliferation index and histologic grade. 
This is relevant because these advanced tumors are the type most likely to be enrolled into 
clinical studies (Grunberg et al., 2006; Wen et al., 2010). 
4.4.1.2 Estrogen Receptor Inhibition 
Estrogen receptor inhibition has been tried in a study on twenty-one patients with non-
resectable refractory meningiomas (Goodwin et al., 1993). Tamoxifen 40 mg/m2 was given 
BID for 4 days, then 10mg BID thereafter. Out of 19 patients that were eligible to continue 
the study, 1 achieved an MRI-documented partial response, while 2 had a minor CT-
documented response of short duration (4 and 20 months). Six patients remained stable for a 
median duration of 31 months, while 10 (53%) demonstrated progression. This study, as 
well as the other rare reports fail to prove the benefits of estrogen receptor inhibition in 
treatment of meningiomas. 
4.4.1.3 Androgen Receptor Inhibition 
Androgen receptor inhibition with flutamide has been tried on a group of 6 patients with no 
response (Wen et al., 2010). There have been no published trials on androgen receptor 
antagonists in meningiomas. 
4.4.2 Chemotherapy 
As with other modalities of systemic treatment, chemotherapy has been mainly used for 
recurrent tumors after the surgical and radiation options have been exhausted. Available 
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data comes from small clinical trials and case series. Further difficulty in interpreting the 
efficacy of chemotherapy is posed by the lack of data regarding the natural history of 
untreated meningiomas (Wen et al., 2010). Overall, most chemotherapeutics have only 
minimal activity against meningiomas.  
4.4.2.1 Dacarbazine, Adriamycin, Ifosphamide and Mesna 
Dacarbazine, adriamycin, ifosphamide and mesna were ineffective in treatment of 
meningiomas.  
4.4.2.2 Combination of Cyclophosphamide, Adriamycin and Vincristine (CAV) 
Combination of cyclophosphamide, adriamycin and vincristine (CAV) was studied on 14 patients 
with primary malignant meningiomas (Chamberlain, 1996). They all underwent surgery 
(gross-total in 4 and sub-total in 10), followed by radiotherapy. Two to four weeks after 
radiotherapy, all patients were treated with adjuvant chemotherapy that included CAV. 
Myelosuppression was the main serious adverse effect. Neuroradiographic response 
included 3 partial responses and 11 with stable disease. The median time to tumor 
progression was 4.6 years and median survival was 5.3 years. The conclusion was that the 
CAV therapy for malignant meningiomas is associated with acceptable toxicity and a 
modest improvement in survival when compared to patients treated with surgery alone.  
4.4.2.3 Temozolomide (TMZ) 
Temozolomide (TMZ) has been ineffective. A phase II study (Chamberlain et al., 2004) was 
conducted on 16 patients with refractory meningioma, previously treated with surgery and 
radiotherapy, but no prior chemotherapy. Temozolomide was administered orally for 42 
consecutive days every 10 weeks. TMZ-related toxicity included anemia (25%), fatigue 
(18.7%), neutropenia (37.5%), seizures (6.3%) and thrombocytopenia (18.7%). None of the 
patients demonstrated a neuroradiographic complete or partial response. 
4.4.2.4 Irinothecan 
Irinothecan  has shown inhibition of meningioma cell growth in vitro, but it was ineffective 
in vivo (Wen et al., 2010). 
4.4.2.5  Hydroxyurea 
Hydroxyurea, an oral ribonucleotide reductase inhibitor, arrests meningioma cell growth in the 
S phase of the cell cycle and induces apoptosis. Preliminary reports on use of hydroxyurea 
appeared promising, but the phase II studies that followed these initial results failed to prove 
significant efficacy. Many of the patients treated with hydroxyurea also received radiation 
therapy, making the interpretation of the results even more difficult (Wen et al., 2010). A phase 
II study of hydroxyurea for unresectable meningiomas (Swinnen et al., 2009) included patients 
with unresectable, measurable, residual or recurrent, histologically proven benign 
meningiomas. The study was closed after 29 patients were accrued, due to the slow subject 
recruitment rate. The objective response rate to chronic hydroxyurea therapy was estimated to 
≤12%. Whether the stable disease rate seen differs in any way from what can be expected from 
the natural history of meningioma could not be determined from this phase II study design.  
Another phase II study of hydroxyurea (Fuentes et al., 2004) included 43 patients presenting 
with unresectable meningioma with clinically and/or neuroradiologically documented 
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progression. They received 20 mg/kg/day of hydroxyurea orally and were followed every 3 
months with physical exam, MRI or CT imaging. Twenty-eight patients underwent surgery. 
Histology was benign in 18 and atypical in 10 patients. Objective response to hydroxyurea was 
found in only 3 patients (7%). Progressive disease was observed clinically or radiologically in 
26 patients (60.5%). Of the eligible population (n=36 with clinically and/or radiologically 
proved progression of the disease at the time of entering the study), 2 achieved an objective 
response and 13 (36%) exhibited stabilization under hydroxyurea therapy, while 21 (58%) 
progressed under treatment. Overall tolerance of treatment was good, but anemia was 
observed in 28%, asthenia in 23.5% patients and skin toxicity in one patient. This study did not 
include any patients with known malignant meningiomas (WHO grade III). 
4.4.2.6 Combinations of Hydroxyurea with Imatinib and with Verapamil 
There are ongoing phase II clinical trials investigating combinations of hydroxyurea with 
imatinib and with verapamil.  
4.4.3 Interferon α 
Recombinant interferon alpha inhibits the growth of meningioma cells in vitro. There are 
several reports on small groups of patients (up to 12) showing resultant stable disease (Wen 
et al., 2010). A group of 6 patients with either a recurrent malignant meningioma or an 
unresectable meningioma was treated with interferon-ǂ (Kaba et al., 1997). Two of the six 
meningiomas were regular, one was atypical and three were malignant. Five of six patients 
exhibited positive response to treatment, with stabilization of the size of the tumor in four 
patients and slight regression in one. The toxicity related to interferon was mild and well 
tolerated, mainly including flu-like symptoms in the beginning of therapy and pain at the 
injection site thereafter. 
A phase II study of patients with recurrent, treatment-refractory, WHO grade I meningiomas 
(Chamberlain & Glantz, 2008) included 35 patients who all received prior surgery, radiotherapy 
and chemotherapy. On radiographic documentation of progressive disease, interferon-ǂ was 
initiated at a dose of 10 million IU/m2, subcutaneously every other day in 4-week long cycles. 
Concurrent dexamethsone was permitted for control of neurologic signs and symptoms. It was 
given orally to 12 patients. All the patients were followed with complete blood count, chemistry 
panel and MRI every 3 months. The main toxicities were fatigue, anemia and leucopenia, which 
required discontinuation in 3 patients and dose reduction in 7 patients. No patients 
demonstrated a neuroradiographic complete or partial response. Twenty-six patients 
demonstrated stable disease after the first 3 cycles of interferon, and 9 had progressive disease. 
The median time to tumor progression was 7 months. All but 3 patients died of disease 
progression. The median overall survival was 8 months (range 3-28 months). In contrast to 
previous small studies, this study was confined to patients who had histologcally documented 
WHO grade I meningiomas that had recurred despite undergoing 1 or more prior surgeries. In 
addition, all patients had failed external beam radiotherapy, half had received stereotactic 
radiotherapy, and nearly all (34 of 35 patients) had progressed despite previous chemotherapy. 
Malignant transformation to a higher grade meningioma may have occurred, and the results 
may be reflective of treating mixed grades of meningiomas. Interferon-ǂ appears to have 
citostatic activity against heavily pretreated, recurrent meningiomas and could be considered as 
a palliative therapy for patients who have failed previous surgery and radiotherapy.   
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4.4.4 Somatostatin Analogs 
Somatostatin receptors are expressed in nearly 90% of meningiomas (Norden et al., 2011; 
Wen et al., 2010).  
4.4.4.1 Octreotide  
There have been anecdotal reports of octreotide (long-acting somatostatin agonist) inhibiting 
growth in human meningiomas, but the small number of patients make the results difficult 
to interpret. 
A report on three patients (Garcia-Luna et al., 1993) diagnosed with unresectable 
meningioma, which were treated with octreotide showed almost perfect tolerance to the 
drug. No change was observed by CT scan at the end of treatment course. The treatment 
was given for 6 to 16 weeks to each patient and the authors considered the short duration of 
the treatment to be a possible culprit in not seeing more favorable results.  
A case report on a 54-year-old female with suspected pituitary adenoma (Jaffrain-Rea et al., 
1998) has shown significant clinical and visual improvement during short-term octreotide 
therapy, contrasting with the lack of neuroradiological evidence of tumor shrinkage. The 
patient subsequently underwent transcranial surgery with a final diagnosis of meningioma. 
In a study of 16 patients with recurrent meningiomas (Chamberlain et al., 2007) who had 
progressed radiographycally after prior surgery, radiotherapy and chemotherapy, presence 
of somatostatin receptors was confirmed using octreotide and SPECT scanning. Patients 
were prospectively treated with octreotide, 2-15 cycles on a monthly schedule, with minimal 
toxicity. The overall progression-free survival was 44% (7 patients) at 6 months. Thirty-one 
percent of patients demonstrated a partial radiographic response. Toxicity was minimal, 
suggesting that somatostatin analogues may offer novel, relatively non-toxic alternative 
treatment for recurrent meningiomas. 
4.4.4.2 Pastreotide  
Pastreotide is a long-acting somatostatin analog with a higher binding affinity for most 
somatostatin receptor subtypes than octreotide. In an open label, single arm phase II trial 
(Norden et al., 2011) pastreotide was given intramuscularly on monthly basis to patients 
with recurrent or progressive intracranial meningioma. Twenty-six participants have been 
accrued, 17 of whom (65%) have atypical/malignant meningiomas with previous radiation 
therapy. Twenty-two tumors show at least intermediate octreotide uptake. There are no 
radiographic responses. Of 22 evaluable patients, 16 (73%) achieved stable disease. Toxicity 
included hyperglycemia in 6 patients and elevated lipase in 2 patients. Pastreotide appears 
to be well tolerated somatostatin analog that is under investigation for heavily pre-treated 
recurrent meningiomas. 
4.4.5 Molecularly Targeted Agents 
An increased understanding of the cell signaling pathways has led to the identification of 
other potential targets for therapeutic intervention. Molecular drugs are designed to target 
the pathways involved in cell growth, proliferation and angiogenesis. Unlike gliomas, 
where the blood-brain barrier limits the penetration of many therapeutic agents, the 
penetration of targeted agents in meningiomas is unlikely to be a major issue (Wen et al., 
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2010). As with the other therapies, data for molecularly targeted agents used on malignant 
meningiomas specifically is unavailable. 
4.4.5.1 Platelet Derived Growth Factor (PDGF)  
Platelet derived growth factor (PDGF) stimulates tumor cell growth in various tumors. 
PDGF receptors are expressed in most meningiomas. In a study of expression of PDGF and 
its receptor in 61 meningiomas by immunohistochemistry and in situ hybridization (Yang & 
Xu, 2001), it was found that almost all expressed PDGFBB and PDGFǃ receptor and the 
positive rate of PDGFAA was 49%. Only 2 meningiomas expressed PDGFǂ receptor. The 
positive rate and immunostaining intensity of PDGFBB and PDGFǃ receptor were higher in 
atypical meningiomas than in benign types. The proliferative activity was found to be 
higher in atypical meningiomas than in benign types, as evaluated by proliferating cell 
nuclear antigen labeling index (PCNA LI). The expression of PDGFBB and PDGFǃ receptor 
was increasing with increase of PCNA LI. Therefore, the conclusion was that the 
overexpression of PDGFBB and PDGFǃ receptor in meningiomas correlates with grade of 
meningiomas and the proliferative activity of meningiomas; PDGFBB/Rǃ autocrine loop 
may play critical role in the pathogenesis of meningiomas. 
Inhibition of PDGF receptors with imatinib was tried in a phase II study, which enrolled 23 
patients with recurrent meningiomas (Wen et al., 2009). Out of 22 eligible patients, 13 had 
benign, 5 atypical and 5 malignant meningiomas. Imatinib was given at a dose of  
600 mg/day for the first 4-week cycle, and then gradually increased to 800 mg/day for 
subsequent cycles. Tissue was available only from minority of patients, but in these 
specimens there was uniform distribution of PDGF receptors. Out of 19 patients evaluable 
for response, 10 had progression at first scan and 9 were stable. There were no complete or 
partial responses. For atypical and malignant meningiomas, median progression-free 
survival was 2 months. The study was closed due to slow subject accrual. It has shown that 
imatinib was well tolerated, but ineffective in treatment of recurrent meningiomas. 
A recent in vitro trial on primary meningioma cells is suggesting synergistic activity of 
imatinib and protease inhibitor and pro-apoptotic agent nelfinavir (Gupta et al., 2007). 
Primary meningioma cells responded better to combination therapy than to imatinib alone. 
Combination was also more effective than imatinib alone on in vivo models. The 
investigation of this combination has still not reached clinical phase. 
The combination of imatinib and hydroxyurea for treatment of recurrent meningioma has been 
tried in a phase II study at Duke University (Wen et al., 2010). The results are not available yet. 
Several other PDGFR inhibitors are undergoing evaluation: tandutinib, dasatinib, nilotinib, 
sunitinib, pazopanib and CHIR 265. They are tried for variety of cancers, and some of them 
might be effective for treatment of meningiomas. 
4.4.5.2 Epidermal Growth Factor Receptor (EGFR) Inhibitors and Antibodies 
Epidermal growth factor receptor (EGFR) is overexpressed in over 60% of meningiomas 
(Johnson & Toms, 2005; Wen et al., 2010). EGF and transforming growth factor ǂ (TGFǂ) 
activate these receptors stimulating meningioma cell proliferation in vitro (Johnson & Toms, 
2005). Increased TGFǂ immunoreactivity in meningioma has been associated with 
aggressive growth. TGFǂ is also present in the surrounding cerebrospinal fluid. In contrast, 
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one immunohistochemical study on 84 meningiomas (36 benign, 29 atypical and 19 
malignant) suggested that atypical meningiomas without EGFR expression had a 
statistically worse prognosis compared to atypical EGFR-expressing tumors (Smith et al., 
2007). The same tendency was not evident in cases of benign or malignant meningiomas. It 
is suspected that the atypical tumors lacking EGFR reactivity utilize potent alternative 
growth-stimulatory pathways. 
EGFR inhibitors erlotinib and gefitinib were evaluated in an open label, single arm, phase II 
study for recurrent malignant meningiomas (Norden et al., 2010). Twenty-five eligible 
patients were enrolled. Sixteen (64%) of them received gefitinib and nine (36%) erlotinib. 
Eight patients (32%) had benign tumors, nine (36%) atypical and eight (32%) malignant. 
There were no objective imaging responses, but 8 patients (32%) maintained stable disease. 
Although treatment was well tolerated, neither gefitinib nor erlotinib appear to have 
significant activity against recurrent meningioma. 
In addition to gefitinib and erlotinib, there is a number of other EGFR inhibitors currently 
undergoing evaluations (lapatinib, neratinib, BIBW2992, PF00299804, ZD6474). These inhibit 
EGFR more effectively or inhibit other tyrosine kinases also, potentially increasing their 
therapeutic benefit (Wen et al., 2010).  
EGFR monoclonal antibodies have been effective for some systemic malignancies, but they 
have not been generally used for brain tumors because of the concern regarding the ability 
to cross blood-brain barrier in sufficient concentration. However, crossing the blood-brain 
barrier is not a factor in most meningiomas, so it is possible that these antibodies may be 
effective in these tumors (Wen et al., 2010). 
4.4.5.3 Angiogenesis Inhibitors 
Inhibition of angiogenesis has been an increasingly important approach to treating various 
cancers. Meningiomas are highly vascular tumors that derive their blood supply predominantly 
from meningeal vessels supplied by external carotid artery, with additional supply from 
cerebral pial vessels (Wen et al., 2010). Data on angiogenesis inhibition in treatment of 
meningioma is very limited. Vascular endothelial growth factor (VEGF) plays a central role in 
tumor angiogenesis. Anti-VEGF monoclonal antibody bevacizumab has significantly improved 
outcome in several systemic malignancies as well as in glioblastoma. At least one case report 
described a partial response in a patient with a progressing anaplastic meningioma (Puchner et 
al., 2010). Inhibitors of VEGF receptors, such as sorafenib and sunitinib have prolonged survival 
in renal cell carcinoma and GIST. Expression of VEGF and VEGFR on meningiomas increases 
with tumor grade (10-fold in malignant meningioma as compared to benign) (Lamszus et al., 
2000). VEGF also plays an important role in the formation of peritumoral edema, which adds to 
the morbidity of these tumors (Provias et al., 1997). Inhibitors of VEGF and VEGFR have the 
potential to inhibit angiogenesis, as well as to decrease peritumoral edema. 
5. Prognosis 
WHO grade III tumors, including malignant meningiomas, are significantly more likely 
to be invasive and have a local recurrence following the initial treatment (even gross 
total resection). Prognosis worsens with the more poor differentiation of the tumors 
(Palma et al., 1997; Park & McLaren, 2009; Pasquier et al., 2008). High mitotic rate is a 
www.intechopen.com
 Meningiomas – Management and Surgery 
 
28
significant prognostic factor, as well as the poor Karnofski performance status (Pasquier 
et al., 2008). This leads to overall shorter survival as compared to patients with WHO 
grade I and II tumors. Several trials have elucidated this observation. 
In a study of 1098 surgically treated patients (Yang et al., 2008), 40 were classified as atypical 
and 24 as anaplastic. 10-year survival and recurrence-free survival rates for patients with 
atypical tumors (WHO grade II) were 90 and 87%, respectively. In contrast, the patients with 
anaplastic (WHO grade III), 3 and 5-year recurrence-free survival rates were 50 and 29%, 
respectively. 
Prognosis is also worse for partially resected tumors as compared to completely resected 
ones. However, the most available data was collected prior to development of adjuvant 
therapies, which do improve prognosis.  
Simpson grade I resection can be reliably performed on convexity meningiomas and 
regardless of malignant histological findings, it can improve prognosis (Wen et al., 2010). 
To better understand the prognostic differences between atypical and malignant meningiomas 
and the influence of extent of surgical excision on post-operative course, 42 cases of atypical 
and 29 of malignant meningiomas were studied (Palma et al., 1997). Survival at 5 and 10 years 
was 95% and 79%, respectively in patients with atypical meningiomas. It was 64.3% and 34.5% 
in patients with malignant meningiomas. Recurrence-free survival and median time to 
recurrence were also significantly longer in patients with atypical meningiomas than in 
patients with malignant tumors: 11.9 versus 2 years and 5 versus 2 years, respectively. Six 
(26%) of the atypical meningiomas became malignant. Simpson grade I resection and location 
in the cerebral convexity, which were closely related, were found to be associated with a 
significantly better clinical course in the entire series. Patients with atypical meningiomas fared 
better than those with malignant meningiomas after incomplete surgical resection, but the 
difference was not statistically significant. This study has shown that radical extirpation and 
histological findings were significantly related to prolonged survival. 
Another study on 13 patients with grade III meningiomas (as defined by WHO 2007 
classification), evaluated their outcomes (Rosenberg et al., 2009). A total of 24 surgeries were 
performed, including 13 primary, 7 salvage and 4 second salvage. Also, 14 courses of 
radiotherapy were administered. A trend was seen toward longer survival for patients who 
had received adjuvant radiotherapy after initial surgery as compared to those treated with 
surgery alone. This study confirmed the older observations of generally poor outcomes for 
malignant meningiomas and the tendency for extended survival in patients receiving 
adjuvant radiotherapy in comparison to those treated only surgically. 
Hisopathological characteristics of tumors have a leading role in bringing the prognosis. It is 
important to keep in mind that tumors that were embolized prior to resection can change 
their microscopic appearance making histological analysis more difficult (Matsuda et al., 
2011; see 4.1). 
6. Conclusion  
Malignant meningiomas display a tendency for post-surgical recurrence, which significantly 
increases for multicentric and recurrent disease. Compared to benign meningiomas, 
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malignant meningiomas also display a shorter interval to recurrence. The information on 
malignant meningiomas as an entity separate from their benign and atypical counterparts is 
scarce, due to their rare occurrence. Furthermore, the classification of tumors has changed 
over the years, making it more difficult to compare the older observations with the new 
ones. There are no randomized prospective trials evaluating any aspect of management of 
these tumors. 
However, from all the available data some general conclusions can be made. The patients 
who undergo complete surgical resection tend to have longer survival than those with 
partial resection. Pre-operative embolization, when feasible, can be helpful in achieving 
better surgical results. Adjuvant radiotherapy has shown significant benefits when it comes 
to progression-free survival rates and overall survival. In unresectable tumors, radiation 
alone can be helpful as well. Systemic therapy, including hormonal, chemotherapy, 
interferon and somatostatin analogs, has for the most part failed to show much benefit. The 
molecularly targeted agents have shown efficacy in tumors requiring systemic treatment. 
Further investigations on malignant meningiomas is warranted in order to improve the 
current treatment practices and ultimately ameliorate the prognosis for patients affected by 
these rare tumors. 
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This book is aimed at neurosurgeons with an interest in updating their knowledge on the latest state of
meningiomas surgery and management. The book is focused at performing a portrait of that what is state of
the art in management of meningiomas. All the chapters have been developed with high quality and including
the most modern approaches for the different aspects they deal with. The book concentrates on those
problems that, although perhaps less common in the day to day routine of the average neurosurgeon, when
present pose a special challenge. This is neither a "how to" book nor a book about meningioma biology. It
presents some of the most relevant aspects in the latest developments for meningioma surgery and
management in a clear and professional manner.
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